Skip to main content
Premium Trial:

Request an Annual Quote

NHLBI Warfarin Trial to Use Trimgen Tests

NEW YORK (GenomeWeb News) — The National Heart Lung and Blood Institute will use TrimGen's eQ-PCR Warfarin Genotyping Kit in a clinical trial designed to find out if a gene-based strategy will benefit patients who are at high risk for warfarin sensitivity.

Sensitivity to the blood-thinning drug can result in a higher risk of thromboembolism and bleeding, and can lead doctors to discontinue the therapy early.

The multi-center study, Clarification of Optimal Anticoagulation through Genetics (COAG), will compare two warfarin dosing approaches, including one group that will receive genotype-guided dosing and another group that will receive dosing using clinical data.

Trimgen said it will contribute the tests used for the study, which will begin in April 2009 and is expected to last until 2012.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.